Chief Financial Officer · Foghorn Therapeutics Inc. (FHTX)

Kristian Humer

FY2024 is the first fiscal year CompBrief holds for Kristian Humer as a named executive officer of Foghorn Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,888,603

Salary $336,458Stock awards $0Bonus $87,000

1st of 5 named executive officers at Foghorn Therapeutics by FY2024 total.

5 named officers on file for Foghorn Therapeutics, FY2024

Kristian Humer’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Foghorn Therapeutics’s whole pay program stands against its peers

  • Foghorn Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on FHTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 5, 2025 (DEF 14A).

Free

Get Kristian Humer’s full pay file as a PDF — free

More than this page: up to 10 years of Kristian’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Kristian Humer compensation by year

Foghorn Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Foghorn Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$336,458
Bonus$87,000
Stock awards$0
Option awards$1,250,797
Non-equity incentive$161,500
Pension and deferred compensation$0
All other$52,848
Total$1,888,603

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Foghorn Therapeutics Inc. DEF 14A filed May 5, 2025, accession 0001193125-25-112091, and prior-year filings.

How this page was built: the Foghorn Therapeutics Inc. filed document, accession 0001193125-25-112091. Every figure is read from that document and cited to the page and table it appears in. Filed May 5, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option275,000—$6.03

Per the Outstanding Equity Awards at Fiscal Year-End table in Foghorn Therapeutics Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Foghorn Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Kristian Humer · this pageChief Financial Officer$1,888,603
Adrian GottschalkPresident and Chief Executive Officer$1,559,562
Anna RivkinChief Business Officer$1,472,584
Steven BellonChief Scientific Officer$902,212
Alfonso Quintas-CardamaChief Medical Officer$769,489

The full Foghorn Therapeutics compensation record

free company brief

This page is one person within Foghorn Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Foghorn Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kristian Humer's compensation dossier · One-time report. No refunds.